Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (Nasdaq: APRE) reported Q3 2025 results and a clinical update on Nov 12, 2025. The company has $13.7M cash and says runway extends into the fourth quarter of 2026. Clinical highlights: APR-1051 (WEE1 inhibitor) showed 3 of 4 patients with stable disease at 100 mg QD in ACESOT-1051; dose escalation advanced to 150 mg QD. ATRN-119 (ATR inhibitor) identified a RP2D of 1,100 mg QD in ABOYA-119 and enrollment is being paused to evaluate combination strategies. Financials: Q3 operating loss was $3.1M and net loss was $3.0M ($0.47 per share).
Aprea (Nasdaq: APRE) reported preliminary Phase 1 ACESOT-1051 data through Sept 17, 2025 and a data cutoff of Oct 19, 2025 showing early signs of activity for WEE1 inhibitor APR-1051.
At the 100 mg dose (Dose Level 6), 3 of 4 patients achieved stable disease by RECIST v1.1, including tumors with FBXW7, CCNE1, KRAS G12V and TP53 alterations. No dose-limiting toxicities were reported and dose escalation has advanced to 150 mg (Dose Level 7). Individual patients remain on treatment up to 145 days. A poster is being presented at the AACR-NCI-EORTC conference.
Aprea Therapeutics (Nasdaq: APRE) identified a recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 in the monotherapy arm of the ABOYA-119 Phase 1/2a study in advanced solid tumors.
The company is pausing further enrollment in once-daily and twice-daily monotherapy arms to prioritize combination strategies (radiation, antibody-drug conjugates, immune checkpoint inhibitors) based on preclinical synergy; current patients will continue therapy without interruption.
Aprea will present updated ABOYA-119 data on Oct 24, 2025 at the AACR-NCI-EORTC conference. Separately, lead WEE1 program APR-1051 is actively enrolling; patients have received doses up to 150 mg once daily with early disease-stabilization signals. Clinical data for APR-1051 are expected to be reported later this month.
Aprea Therapeutics (Nasdaq: APRE) announced two poster presentations at the EORTC‑NCI‑AACR International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct 22–26, 2025.
Two abstracts — updated phase 1 data for APR-1051 (WEE1 inhibitor) and updated phase 1/2a data for ATRN-119 (ATR inhibitor) — will be shown as posters on Oct 24, 2025, 12:30–16:00 ET in Exhibit Hall D. Posters will be posted on Aprea’s Investor Resources page the day of presentation.
Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York. A webcast of the presentation will be accessible for 90 days through the company's investor relations website.
Aprea Therapeutics (Nasdaq: APRE) has reported Q2 2025 financial results and provided updates on its clinical programs. The company's WEE1 inhibitor APR-1051 showed early disease control in three patients during the Phase 1 ACESOT-1051 trial, while their ATR inhibitor ATRN-119 demonstrated activity with seven patients achieving stable disease, including three with tumor shrinkage at 550mg twice daily.
Financially, Aprea reported $16.5 million in cash as of June 30, 2025, expected to fund operations into Q2 2026. The company posted a reduced net loss of $3.2 million ($0.53 per share) compared to $3.5 million in Q2 2024, with decreased R&D expenses of $1.9 million and G&A expenses of $1.6 million.
Aprea Therapeutics (NASDAQ:APRE) has announced promising preclinical and early clinical data for APR-1051, its next-generation oral WEE1 inhibitor, in treating HPV+ head and neck squamous cell carcinoma (HNSCC). The drug demonstrated potent antiproliferative effects with IC₅₀ values between 8.9-230 nM in preclinical studies.
In collaboration with MD Anderson Cancer Center, research showed significant anti-tumor synergy when combining APR-1051 with anti-PD-1 therapies. In the Phase 1 ACESOT-1051 trial, a 62-year-old male patient with advanced HPV+ cancer showed stable disease with 5% tumor reduction at first assessment, with no dose-limiting toxicities reported.
Aprea Therapeutics (NASDAQ: APRE) reported Q1 2025 financial results and provided updates on its clinical programs. The company's ATR inhibitor, ATRN-119, showed promising early anti-tumor activity in the ABOYA-119 trial, with three patients demonstrating tumor shrinkage of 7%, 14%, and 21% in the 550mg twice daily cohort. Their WEE1 inhibitor, APR-1051, is advancing in the ACESOT-1051 Phase 1 trial, now dosing patients at 100mg daily.
Financially, Aprea reported $19.3 million in cash as of March 31, 2025, providing runway into early Q2 2026. The company posted a net loss of $3.9 million ($0.66 per share) for Q1 2025, compared to $2.8 million in Q1 2024. R&D expenses increased to $2.5 million from $1.6 million year-over-year, while G&A expenses slightly decreased to $1.8 million from $1.9 million.
The company expects to report preliminary efficacy data for both clinical programs in the second half of 2025.Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has appointed Michael Grissinger to its Board of Directors. Grissinger brings over 40 years of pharmaceutical business development and strategic transaction experience, including more than two decades at Johnson & Johnson where he served as Vice President and Head of Worldwide Pharmaceutical Licensing and Corporate Development.
During his tenure at Johnson & Johnson, Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was a member of the Immunology R&D/Commercial leadership team. Prior to J&J, he spent 12 years at Ciba-Geigy in finance, marketing, and business development roles. He currently serves on the board of Aprea Therapeutics and three private biotech companies.